Adamed Discovery, Adamed Pharma’s innovative Medicines Development Division, has joined BioInMed, the Polish Union of Innovative Medical Biotechnology Companies. BioInMed brings together companies, scientific institutions and public stakeholders to help build an environment in which medical biotechnology can become a key pillar of Polish innovation and a long-term driver of economic growth. Its role goes beyond fostering cooperation on individual projects, it also includes representing the sector’s interests, engaging in dialogue with decision-makers, promoting systemic solutions that support innovation, and helping define the strategic direction of the industry in Poland.

By joining the initiative, Adamed Discovery becomes part of a wider community working to strengthen the position of Polish medical biotechnology, improve the conditions needed for its development, and support a model in which science, business and public administration act together to bring innovation closer to patients. Participation in BioInMed reflects a commitment not only to advancing research and development, but also to contributing to the creation of a stronger, more ambitious ecosystem for biomedical innovation in Poland.

“Joining BioInMed is for us an opportunity to contribute to a broader conversation about the future of medical biotechnology in Poland. We see great value in working together with other members of the ecosystem to help shape the conditions that will enable innovation to grow, translate scientific advances into real impact, and strengthen Poland’s position in the global biotechnology landscape,” says Dr. Nicolas Beuzen, Director of Innovative Medicines Division.